Provided by Tiger Trade Technology Pte. Ltd.

Ascendis Pharma A/S

247.69
+7.923.30%
Post-market: 247.690.00000.00%19:57 EDT
Volume:1.26M
Turnover:309.17M
Market Cap:16.39B
PE:19.11
High:249.01
Open:239.70
Low:237.23
Close:239.77
52wk High:282.15
52wk Low:186.05
Shares:66.19M
Float Shares:65.54M
Volume Ratio:1.31
T/O Rate:1.92%
Dividend:- -
Dividend Rate:- -
EPS(TTM):12.96
EPS(LYR):-4.4176
ROE:118.78%
ROA:9.58%
PB:9.96
PE(LYR):-56.07

Loading ...

Analysts Offer Insights on Healthcare Companies: Vertex Pharmaceuticals (VRTX), Ascendis Pharma (ASND) and Charles River Labs (CRL)

TIPRANKS
·
Yesterday

Ascendis Pharma A/S Stock (ASND) Moved Down by 12.08% on Sep 15: What Signal Does It Send?

TradingKey
·
Yesterday

Movement Alert|Ascendis Pharma A/S Falls 12.23% in Regular Trading, Termination of Novo Nordisk Obesity Drug Collaboration Triggers Selloff

Market Focus
·
Yesterday

Ascendis Pharma Tumbles on Novo Nordisk Collab Termination

Reuters
·
Sep 15

Ascendis Pharma falls -12.1%

TIPRANKS
·
Sep 15

Sector Update: Healthcare

MT Newswires Live
·
Sep 15

Ascendis Pharma Regains Rights to Weight-Loss Technology; Share Buyback Approved

Dow Jones
·
Sep 15

Ascendis Pharma to regain rights to TransCon technology-based products

TIPRANKS
·
Sep 15

Ascendis Pharma announces $400M share repurchase plan

TIPRANKS
·
Sep 15

Ascendis Pharma a/S - to Regain Exclusive Rights to Transcon Technology in Metabolic and Cardiovascular Diseases

THOMSON REUTERS
·
Sep 15

Press Release: Ascendis Announces Planned $400 Million Share Repurchase Program

Dow Jones
·
Sep 15

Ascendis Pharma SVP & PAO Mads Bodenhoff Disposes of 3,000 Common Shares Worth $810,570

Reuters
·
Sep 10

Ascendis Pharma announces data from reACHin Trial

TIPRANKS
·
Sep 10

Ascendis Pharma Director Lars Holtug Disposes of 236 Shares Worth $62,337.59

Reuters
·
Sep 04

Ascendis Pharma is Maintained at Outperform by Oppenheimer

Dow Jones
·
Sep 03

Ascendis Pharma a/S : Oppenheimer Raises Target Price to $312 from $304

THOMSON REUTERS
·
Sep 02

Oppenheimer Reaffirms Their Buy Rating on Ascendis Pharma (ASND)

TIPRANKS
·
Sep 02

Ascendis Pharma Price Target Maintained with a $327.00/Share by Wedbush

Dow Jones
·
Sep 01

H.C. Wainwright trims Ascendis target, says litigation overhang removed

TIPRANKS
·
Aug 31

Ascendis Pharma a/S : H.c. Wainwright Cuts Target Price to $344 from $345

THOMSON REUTERS
·
Aug 31